The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Background The combination of bortezomib, melphalan, and prednisone is a standard
treatment for patients with newly diagnosed multiple myeloma who are ineligible for …

Background High-dose chemotherapy plus autologous stem-cell transplantation has been
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Background This open-label, randomized, phase 3 study compared melphalan at a dose of
200 mg per square meter of body-surface area plus autologous stem-cell transplantation …